– Preclinical data show VIR-2482 has broad neutralizing potential against all major strains of influenza A from the last 100 years – – Extended half-life observed in Phase 1demonstrates potential for ...

(RTTNews) - Vir Biotechnology Inc. (VIR), which had a lackluster reception to its initial public offering, has gained 35 percent over the last 5 trading days but is still trading below its offering ...

Investors bid its shares way up this year, but the market just slashed their value. But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with ...

Thanks to its newly announced COVID-19 antibody therapy candidates, Vir Biotechnology's (VIR 5.25%) stock is still up more than 10% from the beginning of May and more than 180% from the start of the ...

A small biotechnology company developing potential therapies and vaccines against Covid-19 has received a major funding boost from a large drugmaker. London-based GlaxoSmithKline said Monday it would ...

Vir Biotechnology, a San Francisco-based biotechnology firm, said Wednesday that laboratory testing showed two of its antibody drugs appeared to neutralize the coronavirus that causes Covid-19 and ...

A small biotechnology company focused on antiviral drugs that has lately gained prominence in the fight against Covid-19 has added a division of one of Korea’s largest business conglomerates to its ...

Every time Andrew publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Shares of Vir Biotechnology, a little-known clinical-stage immunology company, surged as much as 38% Monday as fears of a global coronavirus outbreak mounted. The Monday gains for the company, which ...

The antibody latches on to a spot found on both the COVID and SARS coronaviruses. Vir Biotechnology Inc. teamed with WuXi Biologics and Biogen Inc. to rush a potential treatment for COVID-19 patients ...

Vir Biotechnology, a San Francisco-based firm focused on infectious disease, and GlaxoSmithKline, the British drug giant, said Monday that they are beginning a study of an antibody drug aimed at ...

Preliminary, blinded pharmacokinetic and safety data from the first-in-human, randomized, placebo-controlled Phase 1 study, which demonstrate that intramuscular dosing of VIR-2482 was well tolerated ...